Wound Care Solution
Clinical studies with D’OXYVA® (deoxyhemoglobin vasodilator) have shown* extraordinary results for the role of transdermal non-invasive wound care using ultra-purified, non-toxic FDA-cleared molecules, such as CO2, especially when all other approaches failed.
In an ongoing multi-year, multi-country, multi-center, randomized clinical trial on patients with diabetic foot ulcers, D’OXYVA has demonstrated speeding up diabetic wound healing and ultimately wound closure to an average of 5 weeks**.
In addition, D’OXYVA eliminated pain and improved quality of life such as sleep, appetite and mood in just a week in 100% of subjects. No adverse events of any kind were reported during, and years after the studies.
The following images illustrate the typical example of D’OXYVA’s efficacy as a stand-alone non-invasive wound care solution for closing chronic vascular disease-related wounds.
All other advanced and traditional modalities have failed after a year of expert intervention at a leading military hospital. A 5-minute (16g CO2) D’OXYVA was applied twice a day on a thumb and on the wound for a total of 4 weeks and healing continued long after.
Patients and physicians report quicker, more comfortable diabetic wound treatment, wound closure, and overall recovery from trauma, and so-called non-healing chronic wounds related to diabetes and cardiovascular complications.***
D’OXYVA USERS REVIEW
MEASURE / FEEL / SEE RESULTS IN 5 WEEKS**
Over two dozen clinical studies demonstrated outsized results at clinics and at home with zero adverse events. For example, D’OXYVA® (deoxyhemoglobin vasodilator) has been recording significant results also as a varicose vein treatment while delivering major clinical outcomes for well over 90% of users. Average results rounded for display, based on number of enrolled subjects in each clinical study with D’OXYVA and user feedback.
Read D’OXYVA Clinical Evidence >>
Ask your doctor before taking D’OXYVA. For prescription for medical use. Read D’OXYVA Regulatory Statements >>